Adaptive Biotechnologies Corporation
Seattle, Washington, United States · Biotechnology, Health Care, Therapeutics
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the adaptive immune system's biology to transform disease diagnosis and treatment. They develop clinical products aimed at diagnosing and treating diseases using advanced genetic techniques. Their flagship product, clonoSEQ®, is designed to detect minimal residual disease in various blood cancers. The compan
Key facts
- Headquarters
- Seattle, Washington, United States
- Employees
- 670
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Public (ADPT)
- Website
- adaptivebiotech.com
- Company page
Recent activity at Adaptive Biotechnologies Corporation
- : SEC 8-K (5.02):
- : SEC 8-K (1.01): On June 22, 2026, Adaptive Biotechnologies Corporation entered into a Material Definitive Agreement by issuing $345 million of 0% Convertible Senior Notes due 2031. This issuance includes the full exercise of an option by initial purchasers on June 17, 2026, for an additional $45 million. The net proceeds of approximately $334.5 million will be used for various purposes including $25.6 million for capped call transactions, $25.0 million for repurchasing shares, and $156.9 million for the repayment of the OrbiMed Purchase Agreement. The Notes, which do not bear regular interest, will mature on July 1, 2031, and have specific conversion rights for noteholders starting from April 1, 2031.
- : SEC 8-K (8.01): On June 15, 2026, Adaptive Biotechnologies Corporation announced its intention to offer $250 million in convertible senior notes due 2031, aimed at qualified institutional buyers under Rule 144A. The company is also pursuing a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses. An additional 13-day option to purchase up to $37.5 million in notes will be granted to initial purchasers, highlighting strategic financial maneuvers amidst ongoing business restructuring. The press releases related to these announcements (Exhibits 99.1, 99.2, and 99.3) detail the offerings and plans but clarify that they do not constitute an offer to sell or solicit an offer to buy any securities.
- : SEC 8-K (7.01): The company has furnished presentation materials, referred to as the 'Investor Presentation,' intended for use in meetings with investors and analysts starting on January 12, 2026. This presentation may be updated in the future, but the company disclaims any obligation to do so. The attached materials (Exhibit 99.2) are not considered 'filed' for the purposes of the Exchange Act. This disclosure is significant as it reflects the company's engagement with investors and possibly strategic updates on its operations or financial outlook.
- : SEC 8-K (8.01): On December 30, 2025, Adaptive Biotechnologies Corporation announced that its 70% owned subsidiary, Digital Biotechnologies, Inc., achieved an initial closing of its Series A Preferred Stock financing, with expected total proceeds of up to $15 million. Following the completion of this financing round, Adaptive anticipates retaining nearly a 50% ownership interest in Digital Biotechnologies. This event is significant as it will allow Adaptive Biotechnologies to continue consolidating the subsidiary's results in its financial statements, indicating a strategic move to strengthen its position in the biotechnology market amidst financial growth potential.
- : SEC 8-K (8.01): On December 30, 2025, Adaptive Biotechnologies Corporation reported that its 70% owned subsidiary, Digital Biotechnologies, Inc., has held an initial closing of its Series A Preferred Stock financing, aiming for total proceeds of up to $15 million. The completion of this financing round is expected to reduce the Company's ownership interest in Digital Biotechnologies to nearly 50%, while still allowing the Company to consolidate the subsidiary's financial results. The filing includes forward-looking statements concerning the financing's completion and its potential implications for ownership and financial reporting. No significant terms or conditions were disclosed beyond the anticipated proceeds and ownership changes.
- : Adaptive Biotechnologies and Pfizer enter two significant partnerships worth up to $890 million for T-cell receptor research and AI drug discovery.
- : Adaptive and Rapid Addition Announce Partnership for Best-in-class FIX Capabilities
- : Adaptive Biotechnologies Corporation presents clonoSEQ® MRD Testing at the 66th ASH Annual Meeting to showcase its effectiveness in blood cancer treatment.
- : Adaptive Biotechnologies Announces Non-Dilutive Royalty Financing With Orbimed For Up To $250 Million
Adaptive Biotechnologies Corporation funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2022 | Grant | Undisclosed |
Leadership
- Chad Robins, CEO
- Tycho Peterson, CFO
- Francis Lo, Chief People Officer
- Chad Robins, Chief Executive Officer
- Alejandra Gonzalez, Adaptive Hr Director
- Sarah Kinney, Hr Professional With Sphr
- Jeanne Schreuder, Mba, Sphr
- Kyle Piskel, Not Specified
- Ashley Derezes, CPA
- Richard Chaplin, Finance Professional With 30+ Years
- Chris Youmans, Strategic Technology Leader
- Jack Dempsey, Applications Development and Data Engineering
Verified email and direct lines for Adaptive Biotechnologies Corporation’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Adaptive Biotechnologies Corporation files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Adaptive Biotechnologies Corporation in the news
- Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026 - GlobeNewswire (Oct 14, 2026)
- Adaptive Biotechnologies Highlights Role of Highly - GlobeNewswire (Sep 25, 2026)
- Adaptive Biotech (ADPT) Reports 35% Revenue Growth Driven by Strong clonoSEQ Performance in Q1 2026 - Yahoo Finance (Jun 03, 2026)
- Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science - GeekWire (Aug 17, 2026)
- Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering - GlobeNewswire (Jun 15, 2026)
- Adaptive Biotechnologies and Microsoft launch virtual ImmuneRACE study to inform novel COVID-19 diagnostics to address unmet needs in testing - Microsoft Source (May 05, 2020)
- Early prediction of outcomes in DLBCL clinical trials through MRD testing - Endpoints News (Dec 04, 2023)
- Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses - GlobeNewswire (Jun 15, 2026)
Companies similar to Adaptive Biotechnologies Corporation
- Cytokinetics · Biotechnology, Health Care, Therapeutics
- Madrigal Pharmaceuticals · Biotechnology, Health Care, Therapeutics
- Apellis Pharmaceuticals · Biotechnology, Health Care, Therapeutics
- Arcus Biosciences · Biotechnology, Health Care, Therapeutics
- BridgeBio · Biotechnology, Health Care, Therapeutics
About Adaptive Biotechnologies Corporation: questions and answers
What does Adaptive Biotechnologies Corporation do?
Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the adaptive immune system's biology to transform disease diagnosis and treatment. They develop clinical products aimed at diagnosing and treating diseases using advanced genetic techniques. Their flagship product, clonoSEQ®, is designed to detect minimal residual disease in various blood cancers. The compan
Where is Adaptive Biotechnologies Corporation headquartered?
Adaptive Biotechnologies Corporation is headquartered in Seattle, Washington, United States.
How many employees does Adaptive Biotechnologies Corporation have?
Adaptive Biotechnologies Corporation has about 670 employees.
Has Adaptive Biotechnologies Corporation raised funding?
Yes. Fundz has recorded 1 funding event for Adaptive Biotechnologies Corporation. The most recent, Grant of Undisclosed, was in Sep 2022.
Who leads Adaptive Biotechnologies Corporation?
Chad Robins is a CEO at Adaptive Biotechnologies Corporation.
What is the latest news on Adaptive Biotechnologies Corporation?
On Jul 29, 2026, SEC 8-K (5.02):
Is Adaptive Biotechnologies Corporation a public company?
Yes. Adaptive Biotechnologies Corporation is publicly traded under the ticker ADPT.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy